Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS

Rheumatology and Therapy

Volumn 2, Issue 2, 2015, Pages 183-195

  Fan, Hong wei ^a   Ma, Zhi xiang ^a   Chen, Jing ^b   Yang, Xing ye ^b   Cheng, Jun lin ^a   Li, Ying bin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XenoBiotic LaboratoriesInc   (China)

Author keywords

Bioequivalence; Hydroxychloroquine (HCQ); Pharmacokinetics

Indexed keywords

EID: 85036469831     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-015-0012-0     Document Type: Article

References (17)

1. Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet. 2003;42(15):1359–82. DOI: 10.2165/00003088-200342150-00004
2. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin. 1999;39:49–57. DOI: 10.1097/00004397-199903920-00005
3. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318–21. DOI: 10.1136/ard.51.12.1318
4. Anderson RJ. Hydroxychloroquine therapy in rheumatic diseases. Ann Rheum Dis. 1995;44:6–7.
5. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–4. DOI: 10.1056/NEJM199101173240303
6. Nasr G, Sliem H. Silent myocardial ischemia in prediabetics in relation to insulin resistance. J Cardiovasc Dis Res. 2010;1:116–21. DOI: 10.4103/0975-3583.70903
7. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196:756–63. DOI: 10.1016/j.atherosclerosis.2007.01.004
8. El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006;33:50–6.
9. Mercer Emileigh, Rekedal Laura, Garg Rajesh. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14(3):R135. DOI: 10.1186/ar3868
10. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68(2):238–41. DOI: 10.1136/ard.2008.093013
11. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–74. DOI: 10.1111/j.1529-8019.2007.00131.x
12. Costedoat-Chalumeau N, Leroux G, Piette JC, Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine. 2010;77(1):4–5. DOI: 10.1016/j.jbspin.2009.09.007
13. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5((Suppl 1)):S11–5. DOI: 10.1177/096120339600500104
14. McChesney EW, Conway WD, Banks WF, Rogers JE Jr, Shekosky JM. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther. 1966;151:482–93.
15. State Food and Drug Administration (SFDA), Center for Drug Evaluation. Guideline for bioavailability and bioequivalence studies of generic drug products. 2005 (in Chinese).
16. Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol. 1996;41(3):244–6. DOI: 10.1111/j.1365-2125.1996.tb00190.x
17. Guidance for Industry:bioavailability and bioequivalence studies for orally administered drug products—general considerations [M], US Department of Health and Human Services, FDA, 2003.